Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Dale L. Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Brian A. Jonas, Ashwin Kishtagari, Jeffrey E. Lancet, Lori J. Maness, James K. Mangan, Gabriel N. Mannis, Guido Marcucci, Alice S. Mims, Kelsey Moriarty, Moaath K. Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca L. Olin, Mary-Elizabeth Percival, Alexander E. Perl, Amanda Przespolewski, Dinesh S. Rao, Farhad Ravandi, Rory M. Shallis, Paul J. Shami, Eytan M. Stein, Richard M. Stone, Kendra Sweet, Swapna Thota, Geoffrey L. Uy, Pankit Vachhani, Carly J. Cassara, Deborah A. Freedman-Cass, Katie Stehman
Abstract
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. Like AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a myeloid malignancy. It is a rare malignancy characterized by the aggressive proliferation of precursors of plasmacytoid dendritic cells that frequently involves the bone marrow, skin, central nervous system, and other organs and tissues. This discussion section focuses on the diagnosis and management of BPDCN as outlined in the NCCN Guidelines for AML.